rs4926 — SERPING1 Val480Met

Missense variant in C1-inhibitor gene associated with insomnia risk through neuroinflammatory and blood-brain barrier mechanisms

See your personal result for SERPING1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SERPING1 Val480Met — When the Brain's Inflammation Brake Slips

Deep inside the complement cascade, one protein quietly keeps the rest of the immune system from attacking your blood vessels and brain. That protein is C1-inhibitor11 C1-inhibitor
A serine protease inhibitor encoded by SERPING1 on chromosome 11; the only known inhibitor of the classical and lectin complement pathways and the kallikrein-kinin system, encoded by SERPING1. The Val480Met variant (rs4926) — a switch from valine to methionine at position 480 of the C1-inhibitor protein — is common in the general population (the A allele appears in about 21–25% of chromosomes globally), yet has emerged from the largest sleep GWAS ever conducted as an insomnia risk locus.

The Mechanism

C1-inhibitor functions as the master brake on two inflammatory cascades: the complement system22 complement system
A cascade of ~30 plasma proteins that tag pathogens and infected cells for destruction; the classical pathway is activated when C1 binds antibody-antigen complexes and the kallikrein-kinin system33 kallikrein-kinin system
A proteolytic cascade generating bradykinin, a potent vasodilator and vascular permeability factor; C1-inhibitor blocks plasma kallikrein and activated factor XII to prevent uncontrolled bradykinin production. When C1-inhibitor activity is reduced or its regulation perturbed, bradykinin accumulates, causing vasodilation and increased vascular permeability — including at the blood-brain barrier (BBB).

The Val480Met substitution at position 480 sits in the C-terminal region of the C1-inhibitor protein. Bioinformatic tools initially scored this as deleterious (CADD score ~23.5) because valine 480 occupies a conserved position involved in proper protein folding. Functional studies found no major disruption to complement inhibition at physiological concentrations; however, the variant modifies gene expression in stressed tissues and shows a detectable functional signature as a genetic modifier, with A allele carriers demonstrating altered plasma C1-inhibitor behavior in settings of immune challenge.

The sleep connection runs through the neurovascular system. Farfara et al. 201944 Farfara et al. 2019
Farfara D et al. Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits. Glia, 2019 demonstrated in mice that reducing circulating C1-INH by 83% caused BBB permeability, extravasation of plasma proteins into brain parenchyma, microglial activation, elevated IL-1β, IL-6, and TNF-α in brain tissue, and — critically — depressive-like behavior and cognitive impairment. The authors describe C1-INH as "a gatekeeper to the brain via the neurovascular system." IL-1β and TNF-α are established somnogenic cytokines that dysregulate sleep architecture when chronically elevated in the CNS.

A separate role for SERPING1 in the brain emerged from developmental neuroscience. Gorelik et al. 201755 Gorelik et al. 2017
Gorelik A et al. Serping1/C1 Inhibitor Affects Cortical Development in a Cell Autonomous and Non-cell Autonomous Manner. Frontiers in Cellular Neuroscience, 2017 showed that Serping1 knockdown in embryonic mice impaired radial neuronal migration and neural stem cell proliferation through C5a receptor signaling. This suggests SERPING1 variants may subtly alter the complement-mediated pruning and wiring of sleep-relevant cortical and hypothalamic circuits during development.

The Evidence

The primary evidence linking rs4926 to insomnia comes from the landmark GWAS by Jansen et al. 201966 Jansen et al. 2019
Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nature Genetics, 2019. This meta-analysis of 1.33 million individuals identified 202 genome-wide significant loci for insomnia, implicating 956 genes through positional, eQTL, and chromatin interaction mapping. Cell-type enrichment pointed to striatal medium spiny neurons and hypothalamic neurons as key mediators — both of which are embedded in neuroinflammatory circuitry that C1-inhibitor normally dampens. The SERPING1 locus cleared the genome-wide significance threshold, placing it among the most robustly replicated insomnia risk loci from this study.

In a non-sleep context, the A allele's functional footprint is well documented. Parsopoulou et al. 202277 Parsopoulou et al. 2022
Parsopoulou F et al. Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency. Frontiers in Allergy, 2022 studied 233 hereditary angioedema patients and found that rs4926 A allele carriers showed a significant 3.6-year delay in age of disease onset (heterozygote carriers, p = 0.018) and a trend toward a 6.3-year delay in homozygous AA carriers (p = 0.058), independently of the primary SERPING1 disease mutation. This modifier effect — that even on a background of severely impaired C1-INH, the A allele changes disease expression — confirms this variant touches a biologically meaningful control point.

A 2022 study of neonates with lung disease found that AA homozygotes had substantially elevated susceptibility to sepsis (OR = 5.19, 95% CI 1.73–15.6, p = 0.002) and that SERPING1 transcript was most strongly downregulated in A allele carriers under inflammatory stress, suggesting the variant affects expression under immune challenge rather than at baseline.

Practical Actions

The insomnia risk from this SERPING1 variant operates through chronic low-grade neuroinflammation. Interventions that reduce neuroinflammatory tone and support BBB integrity are mechanistically relevant. The complement and kallikrein-kinin pathways are both highly sensitive to long-chain omega-3 fatty acids (EPA/DHA), which inhibit pro-inflammatory eicosanoid production. C1-inhibitor expression is also modulated by androgenic hormones, and sleep itself is necessary for glymphatic clearance of inflammatory debris — meaning insomnia and neuroinflammation can form a self-reinforcing loop.

For AG heterozygotes, the risk increment is modest and manageable through dietary and supplementation strategies that support neuroinflammatory balance. For AA homozygotes, the combined neuroinflammatory burden is more significant, and active monitoring of sleep quality alongside targeted omega-3 supplementation is warranted.

Interactions

The SERPING1 Val480Met variant sits at the intersection of two major inflammatory cascades that interact extensively with other genetic regulators. The factor XII variant rs1801020 (F12-A46T) acts upstream of C1-inhibitor in the kallikrein-kinin pathway — carriers of both a SERPING1 modifier allele and the F12 thrombophilic allele may experience compounded kallikrein-kinin dysregulation. The plasma kallikrein gene KLKB1 rs3733402 similarly interacts with SERPING1 activity to modulate bradykinin production rates. The second SERPING1 modifier SNP rs28362944 may act additively with rs4926 for neuroinflammatory risk tone, though compound data are limited. These interactions are worth investigating if complement pathway profiling is available.

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard C1-Inhibitor Normal

Reference genotype — full C1-inhibitor regulation of complement and kinin pathways

The GG genotype carries the ancestral valine at position 480 of C1-inhibitor. Valine at this position supports proper protein folding and the regulatory activity of C1-INH at both its complement targets (C1r, C1s, MASP1, MASP2) and its kallikrein-kinin targets (plasma kallikrein, activated factor XII). With both alleles intact, the blood-brain barrier receives its full complement of neuroinflammatory regulation, and the somnogenic cytokine environment (IL-1β, TNF-α) remains under normal inhibitory control.

This genotype was the comparator in the Jansen 2019 insomnia GWAS, meaning insomnia risk estimates for A allele carriers are expressed relative to GG individuals like you. Your sleep quality from this locus reflects only your non-genetic risk factors.

AG Reduced C1-Inhibitor Tone Intermediate

One copy of the insomnia risk allele — mildly elevated neuroinflammatory baseline

In heterozygous carriers, one copy of the Val480Met variant is present. The substitution of valine (hydrophobic, rigid side chain) with methionine (longer, more flexible sulfur-containing side chain) at this conserved position does not eliminate C1-inhibitor function but appears to modify its expression under inflammatory stress conditions. The neonatal lung disease study (Elngar 2022) found that A allele carriers showed significantly downregulated SERPING1 transcript in inflamed tissue, suggesting the variant reduces transcriptional response when it matters most.

In hereditary angioedema patients, heterozygous AG carriers showed a 3.6-year delay in symptom onset compared to GG carriers (p = 0.018), demonstrating that one A allele measurably shifts the threshold for C1-inhibitor-regulated inflammatory activity. For sleep, this translates to a modestly elevated neuroinflammatory baseline, particularly during periods of acute illness or chronic low-grade inflammation.

AA Low C1-Inhibitor Tone High Risk

Two copies of the insomnia risk allele — elevated neuroinflammatory baseline affecting sleep and infection resilience

Homozygous AA carriers have both copies of C1-inhibitor producing methionine at position 480. The Elngar 2022 study of neonates found AA genotype was the strongest predictor of SERPING1 downregulation in inflamed tissue (median expression −2.86, IQR −3.55 to −1.71; p < 0.001) and the highest sepsis susceptibility (adjusted OR = 4.26, p = 0.012), directly demonstrating a gene-dosage effect on C1-inhibitor output under stress. This translates to a chronically reduced braking capacity on the kallikrein-kinin and complement cascades in the CNS.

The Farfara 2019 mouse study showed that depleting C1-INH by ~83% is sufficient to cause measurable BBB permeability, neuroglial activation, elevated brain IL-1β and TNF-α, and behavioral depression within weeks. While the AA variant does not eliminate C1-INH function like experimental knockdown, it may chronically shift the neuroinflammatory set point toward the permissive range during immune or metabolic stress. The net result is a higher-baseline somnogenic cytokine environment that dysregulates sleep architecture — manifesting as difficulty initiating or maintaining sleep.

Practically, AA carriers are also more likely to experience prolonged sleep disruption during and after acute illnesses, as inflammatory activation more readily overwhelms their reduced C1-inhibitor reserve.